Abstract
Introduction
Deoxycytidine kinase (DCK) is the rate-limiting enzyme of the intracellular phosphorylation of nucleoside anticancer drugs, including gemcitabine and β-arabinofuranosylcytosine, to their active triphosphates. This study was performed to assess the occurrence and frequency of DCK polymorphisms in a predominantly Caucasian population and to choose candidate polymorphisms for subsequent functionality studies.
Methods and materials
All seven DCK exons and the promoter region were sequenced from 100 healthy volunteers (79 females and 21 males). With respect to ethnicity, the study cohort comprised 93 Caucasian, one Asian, one African, and five mixed-race individuals.
Results
Six novel single nucleotide polymorphisms (SNPs) were found (−243G>T, −135G>C, 261G>A, 364C>T, 727A>C, IVS6+41T>A). Two SNPs are nonsynonymous and lead to changes in the amino acid sequence [C364T in exon 3 (P121S) and A727C in exon 6 (K242Q)]. The presence of the linked promoter polymorphism −360C>G/−201C>T was confirmed in Caucasians, but was less frequent than what has been reported from Asians (allele frequencies 2 versus 15.6%). The most prevalent haplotype was the wild-type plus IVS6+41TT (85.8%). This study found novel DCK polymorphisms, including nonsynonymous SNPs, in exons 3 and 6. A comparison of the data obtained in this study with those reported in a previous study on Asians [Shi et al. (2004) Pharmacogenetics 14:759–768] illustrates marked inter-ethnic differences in the occurrence and frequency of DCK polymorphisms.
Conclusion
The higher allelic frequency of the promoter polymorphism -C360G/-C201T in Asians than in Caucasians might predispose Asians to nucleoside drug-associated toxicity. These data will be used to assess the effect of DCK candidate SNPs (promoter, exons 3 and 6) in patients receiving gemcitabine anticancer treatment.
References
Momparler RL, Fischer GA (1968) Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 243:4298–4304
Song JJ, Walker S, Chen E, Johnson EE, Spychala J, Gribbin T, Mitchell BS (1993) Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc Natl Acad Sci USA 90:431–434
Stegmann AP, Honders MW, Bolk MW, Wessels J, Willemze R, Landegent JE (1993) Assignment of the human deoxycytidine kinase (DCK) gene to chromosome 4 band q13.3-q21.1. Genomics 17:528–529
Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ, Pinedo HM, Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371–376
Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM (2001) Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 7:3263–3268
Shewach DS, Reynolds KK, Hertel L (1992) Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42):518–524
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117
Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ (2004) Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14:759–768
Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495–503
Danson S, Blackhall F, Hulse P, Ranson M (2005) Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28:103–113
Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP (2004) Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 18:85–91
Matsui K, Hirashima T, Nitta T, Kobayashi M, Ogata Y, Furukawa M, Kudoh S, Yoshimura N, Mukohara T, Yamauchi S, Shiraishi S, Kamoi H, Negoro S, Takeda K, Nakagawa K, Takada M, Yana T, Fukuoka M (2005) A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 35:181–187
Acknowledgements
M. Joerger is supported by a fellowship grant funded by the European Society of Medical Oncology and by a research grant from the Swiss National Science Foundation (PBBSB-102331).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Joerger, M., Bosch, T.M., Doodeman, V.D. et al. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 62, 681–684 (2006). https://doi.org/10.1007/s00228-006-0162-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-006-0162-7